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Preface  
Infection of cervical epithelium with high-risk human papillomavirus (hrHPV) might result in 
productive or transforming cervical intraepithelial neoplasia (CIN) lesions, the morphology of which 
can overlap. In transforming CIN lesions aberrations in host cell genes accumulate over time, which is 
necessary for ultimate progression to cancer. On the basis of (epi)genetic changes, early and advanced 
transforming CIN lesions can be distinguished. This paves the way for new molecular tools for 
cervical screening, diagnosis and management of cervical cancer precursor lesions.  
 
Introduction 
With about 530,000 new cases annually, cervical cancer is the third most common cancer in women 
worldwide, and the seventh most common cancer overall. In 2008, cervical cancer was responsible for 
275,000 deaths, thereby being the fourth leading cause of cancer death in females worldwide 1, 2. 
Virtually all cervical cancers result from a persistent infection with certain high-risk types of the 
human papillomavirus (hrHPV) family 3. However, cervical cancer is a rare complication of a rather 
common viral infection; the lifetime risk of a hrHPV infection is estimated to be around 80% and 
fortunately 4, and the large majority of infections are cleared by the host immune system and do not 
give rise to lesions. Most of the remaining hrHPV infections develop into lesions that are thought to 
represent ‘productive’ infections that lead to the generation of new viral progeny. Although such 
infections display no signs of cellular transformation, morphologically they can show dysplastic 
features that overlap with those seen in progressive precancers. Only a minority of hrHPV infections 
become ‘transforming’ infections, characterized by the altered expression of two viral genes, E6 and 
E7 (see below). Such a condition may ultimately lead to cancer if the respective precursor lesion is left 
untreated. It is still poorly understood which factors determine the malignant fate of a hrHPV 
infection. 
Here, we address recent advances that shed more light on the development and progression of 
transforming hrHPV infections.  The focus is on cellular genetic and epigenetic alterations underlying 
the progression to cancer. Their implications for development of new molecular diagnostic tools for 
cervical screening, diagnosis and management of patients with cervical precancer is also discussed.  
 
Cervical cancer and HPV 
According to their epidemiological association with cervical cancer and consolidated by 
biological studies, twelve HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) have now 
been consistently classified as hrHPV (also known as IARC class I). HPV 68 has been classified as 
probable high-risk (also known as IARC class 2A) and another seven types have been classified as 
possible high-risk  (HPV 26, 53, 66, 67, 70, 73 and 82;also known as IARC class 2B) 5.  
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Following a hrHPV infection, cervical cancer develops through a series of subsequent steps: 
hrHPV persistence, hrHPV mediated epithelial transformation, development of precancerous lesions 
(cervical intraepithelial neoplasia graded 1 to 3 (CIN1-3)), and finally progression to invasive cervical 
cancer (FIG. 1). Cervical cancer development, in particular the step from precancer to invasive cancer 
takes a long time in most patients. Whereas high-grade precancerous CIN2 and CIN3 lesions can 
develop within 3-5 years following an hrHPV infection 6, further progression to invasive cancer can 
take up to 20-30 years 7, 8. This long period offers many opportunities for intervention and has 
probably contributed to the success of frequent Pap screening to reduce the incidence and mortality of 
cervical cancer in the Western world 9. 
Histomorphologically, most cervical cancers are squamous cell carcinomas (SCC; accounting 
for 80% of cervical cancers). Adenocarcinomas (AdCA; accounting for 10-20%) represent the second 
most common histotype, followed by a rather small fraction of adeno-squamous carcinomas and other 
rare histotypes including neuro-endocrine carcinomas.  
 
Features of productive versus transforming infections 
A productive infection begins when viral particles gain access to the epithelial basement 
membrane, most likely via micro-abrasions, and subsequently enter the basal cells of squamous 
epithelium. In infected basal cells, the viral genome is replicated in conjunction with cellular DNA 
during S-phase and maintained as stable episomes 10. In these cells, expression of the viral proteins 
occurs at very low levels, which likely facilitates escape from immune surveillance 11-13. Following 
cell division, one of the daughter cells undergoes a differentiation process and exits the cell cycle. 
Subsequently, viral differentiation-dependent promoters become upregulated, resulting in an increased 
expression of viral genes, including the viral early genes E6 and E7. Expression of the E6 and E7 
genes drives the differentiated cells into S-phase, thereby creating environmental conditions 
supporting vegetative viral genome replication. In the upper layer of the squamous epithelium, the last 
stage of the viral life cycle involves generation of new viral particles that are released from shedding 
terminally differentiated cells (reviewed in 14). Productive infections in the cervix may give rise to 
mild to moderate cellular abnormalities, and histologically such conditions are manifested as CIN1 or 
2 (CIN1/CIN2). In order to distinguish this condition from true cancer precursor lesions, such lesions 
are here referred to as productive CIN lesions. Usually, these lesions regress spontaneously within 1-2 
years, a process accompanied with viral clearance resulting from cell-mediated immune responses to 
E2, E6 and E7. Immune evasion accompanied with viral and lesion persistence may result from 
various mechanisms, such as virus-mediated suppression of innate immunity, suppression of T-cell 
effector function, increase in regulatory T cells and frequent loss of HLA expression resulting from 
genetic events (reviewed in 15). Loss of immune control facilitating viral persistence is crucial for 
HPV-mediated carcinogenesis as HPV infections are not only essential for the initiation, but also 
maintenance of the transformed phenotype (reviewed in 16). 
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Morphologically, CIN3 and a subset of CIN2 lesions typify transforming CIN lesions, in 
which the normal viral life cycle is aborted and the viral early genes E6 and E7 are overexpressed in 
proliferating cells.  Morphologically, however CIN2 lesions resulting from a productive infection can  
not be distinguished from CIN2 lesions resulting from a transforming infection. In the context of  
dividing cells, the E6 and E7 encoded proteins act as oncoproteins and the respective genes are 
therefore referred to as viral oncogenes. A direct result from E6 and E7 deregulation in a transforming 
infection is the altered expression of cell cycle and DNA repair regulators. The exact mechanism 
contributing to this rather unnatural E6 and E7 expression pattern has not been understood, but altered 
intraviral control of E6 and E7 expression by genetic (viral DNA integration, for example) and 
epigenetic (methylation of viral promoter regions, for example) alterations of the viral genome have 
been suggested 17-19. Alternatively, a different host cell environment that is non-permissive for viral 
replication could favour non-canonical regulation of E6 and E7 expression. A candidate cell type that 
could be highly susceptible to HPV transformation is the squamo-columnar junction (SCJ) cell. Herfs 
et al.20 recently reported that this discrete population of single layered, cuboidal epithelial cells of 
embryonic origin, which are localized between ectocervical squamous and endocervical glandular 
epithelium, represents the likely cellular precursor of most cervical cancers and their precursor lesions. 
By contrast, productive infections might arise exclusively from infection of basal cells of the 
squamous epithelium lining the ectocervix or adjacent transformation zone 21.  
SCJ cells display a unique gene expression profile for several genes, including Krt7, AGR2, 
MMP7, and GDA 20. The proteins encoded by these genes can serve as an SCJ-specific protein 
biomarker panel. The expression of these proteins is not induced by HPV E6 or E7 in vitro in 
squamous epithelial cells, and expression of these proteins is lost if the SCJ is removed by cone biopsy 
or loop electrical excision. Therefore, it seems that that the SCJ-specific expression profile in CIN 
lesions and cervical cancers is not acquired during the transformation process and instead reflects the 
embryonal origin of the cells. Interestingly, for all cervical cancers analysed (both SCC and AdCA), 
the majority of CIN2/CIN3 lesions, and one third of CIN1 lesions were positive for a SCJ expression 
profile20, 22. The presumed high transformation susceptibility of these SCJ cells compared to squamous 
cells of the ectocervix and transformation zone is supported by the fact that HPV-related high-grade 
precancerous lesions are up to 20 times more common in the cervix (which contains a SCJ) than in 
other genital sites lacking a SCJ, such as vagina and vulva 23. 
The net result of deregulated expression of E6 and E7 in proliferating cells is chromosomal 
instability 14, which likely provides the driving force for accumulation of alterations in cancer genes of 
the host cell and consequently progression towards cancer.  
In the following sections, the primary and secondary consequences of deregulated E6 and E7 
expression on host cell genes and gene products will be discussed in the context of cervical cancer 
development.  
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Primary effects of E6 and E7 deregulation 
It is now widely accepted that combined hyperactivity of E6 and E7 in proliferating cells 
represents the trigger for HPV-induced malignant transformation. Initially, binding of tumour 
suppressor gene products RB by E7 and p53 by E6 were thought to be the primary events responsible 
for malignant transformation. Targeting of RB by E7 leads to uncontrolled cell proliferation, primarily 
resulting from increased E2F activity as evident through the upregulation of E2F responsive genes, 
such as PCNA, Ki-67, minichromosome maintenance proteins (MCMs), cyclin E and p21 (reviewed in 
24, 25). Formation of a complex between the ubiquitin ligase E6AP and E6 results in ubiquitin-mediated 
degradation of p53, thereby interfering with the normal p53-mediated apoptosis- and cell cycle control 
mechanisms induced by genotoxic stress24, 25. 
Nowadays, it has become evident that complex formation of E6 and E7 with other cellular 
proteins also contributes to the virus-mediated transformation process. Some of the interactions result 
in chromatin remodelling (reviewed in 26). Both E6 and E7 can modulate the DNA methylation 
machinery, thereby influencing cellular and viral gene expression. HPV16 E6 can induce upregulation 
of the DNA methyltransferase DNMT1 via suppression of p53 27, whereas HPV16 E7 can directly 
bind and activate DNMT1 28. In support of these in vitro findings, both DNMT1 and DNMT3b were 
shown to be upregulated in CIN3 lesions and cervical carcinomas 29-31. A further modulating effect on 
epigenetic reprogramming can be accomplished by E7 via induction of histone lysine demethylases 
KDM6A and/or KDM6B. This leads to histone demethylation of genes that were silenced by 
polycomb repressive complex (PRC)-mediated histone H3 lysine 27 (K27) tri-methylation32, 33. One of 
these genes encodes the cyclin-dependent kinase inhibitor p16INK4a 33. Although this induction does not 
effect proliferation because of the downstream targeting of RB by E7, overexpression of p16INK4a is 
nowadays widely considered as a hallmark of hrHPV activity (FIG. 2) 34. 
In addition, HPV16 E6 and E7 are also known to alter the expression of miRNAs (BOX 1), 
through direct and indirect effects.  HPV16 E6 can downregulate miR-218, miR-23b and miR-34a 
expression 35-37, the latter two being linked to E6-induced p53 degradation. Reduced miR-203 and 
increased expression of the miR-15a/16-1 cluster is attributed to E2F release upon RB inactivation by 
hrHPV E7 38. Vice versa, miRNAs may also regulate viral gene expression 39, and first indications for 
the existence of HPV-encoded miRNAs have been reported 40. These findings, however, await further 
confirmation.  
 
 
Secondary effects of deregulated E6 and E7 expression  
Although E6 and E7 are necessary for initiation and maintenance of the transformed 
phenotype, the long duration of progression from precancer to invasive cancer indicates that several 
additional oncogenic events are pivotal for malignant progression. A well known consequence of 
deregulated E6 and E7 expression is chromosomal instability (reviewed in 24). This genomic instability 
likely contributes to the accumulation of aberrations in host cell genes over time (FIG.2). Such 
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acquired aberrations can be both genetic and epigenetic, and some of them result in functional 
abrogation of human tumour suppressor genes or activation of oncogenes. Host cell aberrations 
observed in cervical (pre)cancers include deletions, copy number alterations, DNA mutations, and 
epigenetic alterations, such as DNA methylation affecting both protein coding genes and non-coding 
genes like miRNAs. An overview is available in the form of a recently established database of genes 
that have been found to be altered in cervical cancer 41. In the following sections, various aberrations 
in cervical cancers and CIN lesions are described. 
  
Chromosomal aberrations 
A meta-analysis of 12 array comparative genomic hybridization (aCGH) studies covering a 
total of 293 samples showed that the most frequent DNA copy number alterations in cervical SCC 
include gain at 3q (rate 0.55), loss at 3p (rate 0.36) and loss at 11q (rate 0.33) 42. Gain at 3q was 
particularly frequent in HPV16-positive SCC (rate 0.84). Gain at 17q (rate 0.36) was most frequent in 
AdCA (4 studies, 58 samples). Gain at 1p was the most frequent aberration in high-grade CIN (rate 
0.34). This was followed in decreasing order of frequency (from 0.27 to 0.08) by gain at 3q, loss at 4q, 
2q, 4p, 11p and 3p. From these regions candidate driver genes can be extracted by analysis of 
recurrent focal aberrations and/or expression profiling supplemented with functional analysis. This 
approach has led to the identification of EYA2 and hsa-mir-375 as novel onco- and tumour suppressor 
genes, respectively, in cervical cancer 43. In support of these findings, EYA2 has recently been 
identified as a target of viral integration and a tumour suppressive function of miR-375 has also been 
corroborated in other studies 44, 45. These data provide a proof-of-concept that specific chromosomal 
aberrations can contribute to HPV-induced carcinogenesis.  
 
DNA mutations  
To date, relatively few reports on mutations in oncogenes or tumour suppressor genes have 
been described for cervical cancer or its precursor lesions. Because p53 and RB are inactivated by E6 
and E7 they are only rarely mutated in cervical cancer (5% and 3%, respectively) [Cosmic catalogue 
of somatic mutations]46. Other somatic mutations found in cervical cancers mainly involve members 
of signalling pathways. Highest mutation rates are reported for PIK3CA in both SCC and AdCA, as 
corroborated in two recent papers (i.e., mutations rates in SCC: 37.5% and 14%, respectively; 
mutation rates in AdCA: 25% and 16%, respectively) 47, 48.  Wright et al. 47 also identified KRAS 
mutations in AdCA only (17.5%), and EGFR mutations in SCC only (7.5%). Ojesina et al. 48 in 
addition showed recurrent mutations in EP300 (16%), FBXW7 (15%), HLA-B (9%), MAPK1 (8%), 
PTEN (6%), STK11 (4%) and NFE2L2 (4%) in SCC, and ELF3 (13%) and CBFB (8%) in AdCA.  So 
far, CIN lesions have neither been studied, nor been analysed at substantial sample size.  
 
Aberrant DNA methylation  
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Epigenetic mediators include histone modifications, nucleosome occupancy and positioning, 
protein and non-coding RNA interactions as well as direct DNA modifications (reviewed in 49). In 
cervical lesions, DNA methylation has gained most attention. This involves the covalent binding of a 
methyl-group (CH3) at the carbon-5 position of cytosine located 5’ of a guanine, to generate a 5-
methylcytosine. In general, increased methylation of CpG-rich human gene promoters represses gene 
transcription, and often involves (candidate) tumour suppressor genes. On the other hand, methylation 
of viral DNA is thought to both negatively and positively regulate viral gene transcription.  
A rapidly growing number of studies have analysed the occurrence and role of viral DNA 
methylation in the development of cervical cancer. Although an altered HPV methylation pattern with 
disease progression is a common finding, being most pronounced in the L1 and L2 regions, data are 
inconsistent (reviewed in 50, 51). Besides technical differences and differences in the CpG sites 
analysed, the nature of the samples may account for the discrepant findings. It is currently unclear 
whether viral methylation is of any biological significance to malignant transformation in terms of 
providing the infected cell with a growth advantage. It has been suggested that viral DNA methylation 
represents a generic phenomenon of de novo methylation of foreign DNA, serving as a host defence 
mechanism to silence viral replication and transcription 52, 53. DNA methylation of the viral upstream 
regulatory region (URR) has been associated with latent infection, which is proposed to facilitate and 
preserve a long-latency infection 54. Methylation of the four E2 binding sites (E2BS; each containing 
one or two CpG dinucleotides) in the viral URR reduces E2 binding 55, thereby contributing to 
deregulated E6 and E7 expression, the driving force of a transforming HPV infection. A gradual 
increase in E2BS methylation is thought to result in a further increase in E6 and E7 expression during 
disease progression. In line with this concept, methylation of the E2BS has been reported to increase 
with disease progression, with methylation at E2BS2 in the HPV16 enhancer region being the most 
consistent finding across the various methylation studies 50, 51.   
Aberrant methylation patterns have been described for a diverse number of (candidate) tumour 
suppressor genes in CIN lesions and cervical cancers (reviewed in 56, 57). The methylation patterns are 
in part histotype dependent, with CADM1, CDH1, DAPK1, EPB4L3 FAM19A4, MAL, PAX1, 
PRDM14 and TERT belonging to the most frequently methylated genes in both SCC and AdCA.  Of 
these genes in transforming CIN lesions, the weighted mean methylation frequencies were highest for 
CADM1, followed by CDH1, DAPK1 and TERT 56. A number of recent genome-wide methylation 
profiling studies have identified a substantial number of additional genes that are methylated in CIN 
lesions and cervical cancers, findings that warrant further validation studies 58-63. For a small subset of 
genes, including CADM1, DKK3, MAL, SFRP2 and C13orf18, tumour suppressive activity in cervical 
cancer cells has been demonstrated 64-69. The biological relevance of most other methylation events 
described in cervical lesions remains elusive.  
 
miRNAs 
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Several genome wide studies on miRNA expression in cervical carcinomas have resulted in 
the identification of a relatively low number of miRNAs that are consistently altered across studies. 
These include miR-126, miR-143, and miR-145 down-regulation and miR-15b, miR-16, miR-146a, 
and miR-155 up-regulation (reviewed in REFs39, 70, 71). For a larger number of miRNAs that might 
have altered expression further independent validation studies are required. Another future challenge 
includes the identification of the target genes affected by the altered miRNAs and determination of 
their functional relevance in HPV-induced transformation. Only for a small fraction of miRNAs (miR-
9, -203, -375, -143, -145, -146a and -199a), has a mechanistic role been shown in cervical cancer cells 
or HPV-immortalized cells 43, 72-76. Four studies that included transforming CIN lesions in their 
analysis showed that altered expression of a number of miRNAs represents a rather early event in 
HPV-induced carcinogenesis detectable in CIN lesions (BOX 1 and Supplementary TABLE 1) 77-80. 
Most miRNA alterations, however, are not directly induced following an HPV-infection, and are 
secondary alterations 77 that might in part be a consequence of a copy number gain at chromosome 5p 
encoding the microRNA processor Drosha 81, 82. Downregulation of miRNAs could be accomplished 
by methylation of the CpG rich regulatory sequences. Indeed, downregulation of hsa-miR-124-1, hsa-
miR-124-2, hsa-miR-124-3, hsa-miR-149, hsa-miR-203, hsa-miR-375, hsa-miR-641 and hsa-miR-1287 
in cervical cancers has been linked to increased promoter methylation of respective genes 73, 74, 83, 84.  
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Duration of existence of transforming CIN is reflected by molecular profile 
As indicated above, CIN3 lesions and a subset of CIN2 lesions constitute transforming CIN 
lesions. Whereas CIN3 is morphologically regarded as the immediate, most advanced cervical cancer 
precursor, it in fact represents a rather heterogeneous disease 85-87. This heterogeneity likely reflects 
variable duration of lesion existence relative to the long time line of 20-30 years necessary for 
progression to invasive carcinoma in most patients 8. In addition, natural history studies have revealed 
that, if not treated, only a subset of CIN3 lesions would progress to invasive cancer 7, 88. Therefore, the 
short-term risk of progression of transforming CIN to cancer is highly variable. Cross-sectional studies 
have revealed variable frequencies of (epi)genetic alterations in CIN lesions and cervical scrapings  
thereof (reviewed in 42, 57, 89,  Supplementary TABLE 2). Since some of the observed molecular 
aberrations overlap with those found in cervical cancers, it seems obvious that these molecular 
changes represent more advanced transforming CIN lesions having a longer duration of existence. 
This is supported by recent findings showing that a longer duration of preceding HPV infection, 
considered as a surrogate for duration of existence of a transforming CIN, is associated with an 
increase in the number of chromosomal aberrations 90. Transforming CIN found in women with long-
term preceding hrHPV infections (≥5 years) had a significantly higher average percentage of 
chromosomal aberrations (i.e.16.5% of microarrayCGH (maCGH) probes deviated from normal state) 
than women with a preceding HPV infection of less than 5 years (2.8% deviating maCGH probes). By 
comparison, CIN3 lesions adjacent to cervical SCC, considered representatives of most advanced, 
transforming CIN lesions, had on average 28.8% deviating maCGH probes. The genomic profiles of 
most CIN3 with a long-term preceding hrHPV infection were similar to those of invasive carcinomas 
and tumour adjacent CIN3. More recently, it was also found that methylation levels of two host cell 
genes, CADM1 and MAL, in cervical scrapings were increased in CIN3 lesions of women with long-
term preceding hrHPV infections, and reached the highest values in women with cervical cancer 91. 
These data are fully in line with the concept that an increase in specific genetic and epigenetic 
alterations reflects a longer duration of existence of the underlying lesion.  
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Biomarkers for cervical cancer screening 
 Due to its high sensitivity for detecting CIN2, CIN3 and cervical cancer (i.e. CIN2 + lesions), 
testing for hrHPV-DNA is likely to become the predominant method for cervical screening in the 
western world in the near future 92, 93. The main drawback of this screening tool is a 2-4% lower 
specificity for CIN2+ than cytology, since the hrHPV test also detects transient HPV infections, 
resulting in overdiagnosis and overtreatment. To compensate for this limitation different triage 
algorithms have been suggested in order to keep the follow-up procedures, and associated costs, within 
acceptable limits. Cytology, with and without HPV 16/18 genotyping is a currently widely-accepted 
triage tool for HPV-positive women 94, 95 96. Alternative algorithms to triage HPV-positive women for 
colposcopy are based on morphological or molecular biomarkers. For biomarker validation in cervical 
screening  a 5-phase framework has been proposed 97 based on  recommendations made by Pepe et al. 
on biomarker development for early detection of cancer 98, 99.The designated phases are: 1) preclinical 
exploratory studies; 2) clinical assay development for clinical disease and assessment in non-invasive 
samples; 3) retrospective longitudinal repository studies; 4) prospective screening studies and 5) 
prospective intervention studies. Phase 5 preferentially concerns a population-based randomised 
controlled trial where a new biomarker test is applied and evaluated against the reference.  
At present most biomarkers are in phase 1 or 2 and only a few have achieved later phases (see below). 
 
 
Morphological biomarkers for triage of HPV-positive women  
Cross-sectional and longitudinal studies have shown that p16INK4A or p16INK4A and Ki-67 dual 
immunostaining on cytological preparations provides a promising triage strategy for HPV-positive 
women 100, 101. Other candidates explored by immunostaining include overexpression of topoisomerase 
2A (TOP2A) and MCM2, which reflects aberrant S-phase induction and correlates with severity of 
cervical disease (reviewed in 102 and 103). 
 These immunohistochemical candidate triage tests, however, are microscopy-dependent and 
require the use of a well fixed specimen with preserved morphology and a skilled (cyto)pathologist. 
Recently, self-sampling of cervico-vaginal material has proved to be a promising new sampling 
technique for hrHPV testing. However, these specimens have shown decreased number of cervical 
cells with often poor morphology in a background of excess vaginal cells resulting in low sensitivity 
of cytology for transforming CIN. A systematic review and a meta-analysis showed that hrHPV 
testing on self-samples can be similarly accurate as on physician-taken cervical scrapings when a 
validated combination of sampling device and HPV test is used 104, 105, whereas cytology has shown to 
be inferior on self-samples 106. Accordingly, triage of women with an hrHPV-positive self-sample by 
cytology-based tests would require an extra visit to the physician for making a cervical smear for 
cytological examination. Therefore, molecular, non-morphology-based triage tools, which are also 
directly applicable to self-samples, are of great interest for future cervical screening programs. 
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Molecular biomarkers for triaging HPV-positive women  
To date, molecular biomarkers based on DNA methylation have gained most attention, 
because altered DNA methylation in cervical cancer has been well established and DNA methylation 
can be easily detected in both histological and cytological cervical specimens. Other cellular gene 
alterations, such as DNA mutations and DNA copy number aberrations, are currently less attractive as 
molecular triage markers. DNA mutations in transforming CIN are not sufficiently well defined to be 
used as a triage marker. Moreover, studies on cancers indicate that mutations in proto-oncogenes or 
tumour suppressor genes are insufficiently prevalent to enable the identification of all cancers 47, 48. 
Although being better defined, the detection of DNA copy number aberrations in cervical scrapings is 
expected to suffer from relatively limited sensitivity for advanced disease by current assays due to a 
dilution of cells from the lesion, and therefore awaits further technical developments and clinical 
evaluation. Conversely, a number of sensitive methods are available to analyse DNA methylation in 
cervical scrapings and cervico-vaginal self-samples (BOX 2).  
Current data on methylated host cell gene promoters investigated in cervical scrapings are 
shown in supplementary TABLE 2. Studies on HPV DNA methylation have recently been reviewed 
elsewhere 50, 51, and combinations based on viral and host cell gene promoter methylation are currently 
being explored 107.  
So far, only a limited number of the host cell methylation markers have been extensively 
tested for their use as triage marker of HPV-positive women. These studies indicate that a panel of 
methylation markers is needed to reach high sensitivities for transforming CIN. These include various 
combinations of the markers SOX1, PAX1, LMX1A and NKX6-1 108, the four-marker panel JAM3-
EPB41L3-TERT-C13ORF18 109, and the bi-marker panel CADM1-MAL 110.  With respect to the 5-
phase frame work of biomarker validation 97, most markers or marker panels tested on cervical 
scrapings have so far only reached early phases. One biomarker panel (i.e. CADM1-MAL)  has been 
validated in a population-based screening setting, thereby reaching phases 3 and 4 of the biomarker 
validation framework. On HPV-positive cervical scrapings this panel was, depending on the threshold 
setting,  equally discriminatory for CIN3+ as cytology at similar specificity 111.   
For HPV-positive self-samples, methylation analysis various marker combinations, such as 
JAM3-EPB41L3-TERT-C13ORF18 and MAL-hsa-miR-124-2, appeared a feasible triage tool 109, 112. 
The use of methylation analyses would obviate the need for HPV-positive women to make an extra 
visit to a physician for a subsequent cervical sample for morphology-based triage testing. The MAL-
hsa-miR-124-2 panel recently passed the later phases of biomarker validation by  first a test-definition 
on self-samples collected in a prospective screening study 112,and subsequently a prospective, 
randomised clinical trial with intervention among non-attendees of the regular cervical screening 
programme 113. In this latter trial DNA methylation analysis using the MAL-hsa-miR124-2 panel on 
HPV-positive self-samples (intervention arm) was compared with an additional physician-collected 
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cervical scraping (control arm) for CIN2+ detection. The results indicate that direct DNA methylation-
based molecular triage was at least as sensitive as cytology triage in the detection of CIN2+ 113. Unlike 
cytology, methylation analysis on self-samples scored all women with cervical carcinoma positive. 
The results also showed a better compliance and shorter diagnostic track, but at the cost of a higher 
colposcopy referral rate.  
 The question can be raised whether methylation markers can be used in clinical practice since 
these markers do not detect all CIN3 lesions and tend to detect less CIN2 lesions than cytology at the 
same specificity 111.  However, these markers can still be considered eligible for triage when 1) they at 
least detect all invasive cancers and advanced transforming CIN with a high short-term progression 
risk for cancer, and 2) test-negative women have a sufficiently low risk of cervical cancer that they can 
be dismissed from direct colposcopy referral.  
In this context the following observations are important. Increasing  methylation levels of genes like 
CADM1 and MAL have been shown to parallel the increasing severity and duration of CIN disease. 
High methylation levels of CADM1 and MAL were detected in cervical scrapings of women with  
advanced transforming CIN lesions and methylation levels in scrapings of women with cervical cancer 
were exceptionally high 91. Consistent with these findings several studies showed that all (100%) 
cervical scrapings of women with underlying cervical cancer were positive for DNA methylation 
using PAX1 (n=14), TIMP3 (n=11), or a tri-marker panel consisting of CADM1, MAL and hsa-
miR124-2 genes (n=79) (L., de Strooper and M., van Zummeren, personal communication) 114, 115. 
From these findings it can be concluded that methylation analysis detects with a high sensitivity 
cancer and advanced lesions with a high short-term progression risk for cancer, thereby missing less 
advanced lesions with a likely low short-term probability of progression to cancer. Cytology, on the 
other hand, detects with a moderate sensitivity all morphological cellular abnormalities associated 
with most CIN2, CIN3 and cancer (schematically depicted in FIG. 3), but misses a fraction of 
advanced transforming CIN lesions and cancers 116, 117.    
This concept implicates that HPV positive women with a positive methylation test should be 
sent for colposcopy because of the presence of cancer or advanced transforming CIN lesions with a 
high short-term progression risk for cancer. It follows that methylation negative women are not in 
need of immediate colposcopy because of a very low short-term progression risk for cancer. Instead, 
these women could be offered a repeat test after 12-18 months. For pregnant women this approach 
appears particularly important as only treatment of methylation positive lesions is indicated thereby 
limiting the risk of preterm delivery resulting from treatment. 118-120. 
The above mentioned methylation studies also point to the possibility of using methylation 
analysis as primary screening tool in cervical screening. When these findings, in particular the high 
sensitivity for cancer, can be confirmed by others, primary methylation testing may provide a screen 
and treat approach in developing countries. This is particularly attractive, since in such countries 
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quality controlled cytology is absent and implementation of follow-up algorithms for HPV-positive 
women is very complicated.  
 
Molecular markers in management of CIN lesions  
In most European countries, women treated for CIN2 and CIN3 are monitored by cervical 
cytology at 6, 12 and 24 months after treatment. After three consecutive negative test results, women 
return to the screening programme (interval 3-5 years), or are recalled within 5 years. Recently, the 
risk of recurrent CIN2+ disease proved to be similar when combined cytology and hrHPV testing at 6 
and 24 months only was used 121, 122. 
An interesting perspective is the surveillance of women treated for CIN2+ disease using a 
combination of hrHPV testing and methylation marker analysis. Residual advanced CIN2 or CIN3 
lesions that result from incomplete excision of the original CIN lesion are expected to have higher 
methylation levels compared to de-novo or incident recurrent CIN2+ lesions because of their longer 
duration of existence. Awaiting clinical confirmation, this would imply that methylation marker 
testing could be helpful in differentiating between cervical cancer and advanced CIN2 and CIN3 
lesions that result from residual disease, and de-novo or incident CIN2 and CIN3 disease. The clinical 
value of post-treatment monitoring by combined HPV and methylation marker testing is currently 
being evaluated (M., Uijterwaal, personal communication). If successful, it is anticipated that in the 
future women treated for CIN2/CIN3 could self-collect a cervico-vaginal specimen for post-treatment 
surveillance by combined HPV and methylation marker testing.  
 
Post-vaccination and therapeutic options 
Prophylactic vaccination against HPV 16 and 18 has been introduced in many countries. In 
post-vaccination screening cohorts, the probability of a high-grade lesion after a positive screening 
result, either by cytology or an HPV test, will be lower. In this context, the use of a methylation 
marker assay might help to identify women with progressive CIN lesions with a high short-term 
cancer risk in need of treatment, and to prevent overtreatment.   
Current advances in genome-wide analyses uncovering of the molecular alterations driving 
cervical carcinogenesis will also provide the opportunity for targeted drug development, such as small 
molecules targeting altered cancer genes, and personalized treatment regimens. The reversible nature 
of the epigenetic alterations in transforming CIN and cervical cancers offers alternative options for 
pharmaceutical intervention. Demethylating agents, such as 5-azacytidine and decitabin (5-aza-2'-
deoxycytidine), have been approved by the US Food and Drug administration for treatment of 
haematological malignancies, and are in phase I clinical trials for the treatment of solid tumours. Their 
application is limited by a high toxicity and poor chemical stability. DNMT inhibitors, such as 
zebularine and small non-nucleoside analogs, are being developed, but await clinical testing 123.  
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Future perspectives  
The distinction between productive CIN1/CIN2 lesions and transforming CIN2/CIN3 lesions has 
consequences for clinical management of women with these lesions. At present, a productive CIN2 
and a transforming CIN2 cannot be distinguished morphologically, resulting in overtreatment of these 
lesions. Uncovering the molecular alterations that are associated with the transition from viral 
infection to cervical cancer can be used for a molecular classification of cervical lesions over and 
above the currently existing morphological (histological) one, i.e., CIN1, CIN2 and CIN3. The 
histological changes currently reported as CIN1/CIN2 lesions that coincide with viral production 
(productive CIN), which has a very low cancer progression rate, can be distinguished from 
CIN2/CIN3 representing viral transformation (transforming CIN), by molecular means. Transforming 
CIN can in turn be subdivided by the level of genetic and epigenetic alterations, such as DNA copy 
number aberrations and DNA methylation, into early and advanced transforming CIN. Women with 
early transforming CIN, characterized by low levels of molecular aberrations, have a low short-term 
progression risk for cancer and could be managed by close surveillance. Women with advanced 
transforming CIN, characterized by increased levels of molecular aberrations, have a high short-term 
progression risk for cancer and are in need of immediate treatment. Accordingly, the detection of 
increased DNA methylation provides an indication for treatment of CIN2/CIN3 lesions. This 
molecular distinction allows for better management of women diagnosed with CIN lesions, and may 
particularly be beneficial to women of reproductive age, as treatment of CIN lesions coincides with 
some degree of morbidity of the cervix and can give rise to pre-term delivery 118-120.  
HPV testing is likely to become the primary screening tool for cervical cancer. Due to the slightly 
lower specificity compared to cytology-based screening, triage of hrHPV-positive women is required 
in order to keep follow-up procedures and associated costs within acceptable limits. The increase in 
DNA methylation of tumor suppressor genes associated with the development of advanced 
transforming CIN and cervical cancer provides valuable objective molecular triage markers. Such 
markers are likely to replace current triage algorithms based on cytology, with or without HPV 16/18 
genotyping. DNA methylation can be easily detected in cervical scrapings and self-samples and 
methylation analysis has a high sensitivity for cervical cancer and advanced transforming CIN lesions 
in both sample types. The compatibility of methylation markers with HPV testing and self-sampling 
allows for full molecular cervical screening in the near future. In addition, the methylation markers 
could provide molecular tools to monitor women for post-treatment CIN2+. 
 In conclusion, recent insight in genetic and epigenetic changes associated with cervical cancer 
development has offered opportunities for molecular distinction of cervical cancer precursor lesions, 
paving the way for new biomarkers useful for screening, diagnosis and management of cervical cancer 
precursor lesions.  
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Key Points Summary 
 
 
• CIN lesions can be divided into productive CIN (CIN1/2) and transforming CIN 
(CIN2/3). Morphologically, productive CIN2 can not be distinguished from transforming CIN2.  
• Transforming CIN reflects a heterogeneous disease.  Early and advanced transforming 
CIN lesions, displaying a low- and high short-term progression risk for cancer, 
respectively, can be distinguished on the basis of molecular host cell alterations.  
• When applied to cervical scrapings specific methylation markers, such as CADM1, MAL 
and miR124-2, detect advanced transforming CIN and cancer with a high sensitivity. 
• CIN 2/3 lesions detected by specific methylation markers are in need of immediate 
treatment given their high short-term progression risk for cancer. 
• Cytology detects with a moderate sensitivity morphological cellular abnormalities associated with  
CIN2, CIN3 and cancer, but may miss cancer and advanced transforming CIN with a high short-
term progression risk for cancer.     
• HPV testing will replace cytology as primary screening tool for cervical cancer.  
• Clinically validated panels of methylation markers, such as CADM1, MAL and miR124-2, 
can be used as triage marker for HPV positive women.   
• Methylation marker panels with a high sensitivity for cancer, such as CADM1, MAL and 
miR124-2,  have the potential to serve as primary screening tool.  
• DNA methylation marker panels may in addition be used for  management of women with 
CIN lesions to prevent overtreatment of CIN2/3 lesions.  
• The compatibility of methylation markers with HPV testing and self-sampling has the 
potential for full molecular cervical screening in the near future. 
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BOX1: microRNAs and their differential expression in transforming CIN 
MicroRNAs (miRNAs) are noncoding regulatory RNAs of 18-25 nucleotides in length, that 
can bind to the 3′ untranslated regions (3′UTR) of target mRNAs, thereby inhibiting protein 
translation, mRNA degradation, or both. As such, altered expression of miRNAs may affect tumour 
suppressor or oncogene protein expression. To date, more than 2500 human mature miRNAs have 
been annotated in the miRNA database (miRBase 20, release date June 2013; www.mirbase.org). 
miRNA expression profiles are highly tissue- and/or differentiation-specific, and often altered in 
cancers, which may at least in part result from DNA copy number alterations as well as epigenetic 
alterations 124. 
A summary of differentially expressed miRNAs in transforming cervical intraepithelial 
neoplasia (CIN) lesions compared to normal cervical biopsies, and of which altered expression persists 
or increases in cervical carcinomas, is listed in TABLE 1. At present, there is relatively little overlap 
in altered miRNAs detected in the various studies and further research using independent platforms is 
warranted to extract the most powerful miRNA signature(s) predicting cervical cancer risk. 
Nonetheless, preliminary data indicate that miRNA expression analysis of a subset of differentially 
expressed miRNAs in cervical scrapings enables the detection of underlying transforming CIN (S., 
Wilting, personal communication)  
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BOX2: Methods for DNA methylation detection applicable to cervical scrapings and self-
samples 
Sensitive methods to detect aberrant DNA methylation in cervical scrapings or self-samples 
include (quantitative) methylation specific PCR ((q)MSP), MethyLight, methylation-specific high-
resolution melting (MS-HRM) analysis and pyrosequencing. Each of these techniques is based on 
sodium bisulfite treatment of DNA resulting in conversion of unmethylated cytosines into uracils, 
while leaving methylated cytosines unaffected. This allows for DNA methylation mapping at single 
base resolution. which can be detected by PCR amplification and sequencing. qMSP, MethyLight and 
HS-HRM have similar analytical sensitivities and can detect as little as 0.1–1.0% of methylated DNA 
in a background of unmethylated DNA 125-127. The sensitivity for bisulfite pyrosequencing is 
approximately 5% 128. Although the sensitivity of bisulfite sequencing analysis can be increased when 
converted to a massive parallel sequencing-by-synthesis approach 129, its high-throughput application 
on large sample series awaits further developments. 
 A major advantage of the quantitative real-time PCR technologies is the option to analyse 
multiple methylation targets and an internal control in a multiplex reaction using a single aliquot of 
sample material, thereby saving material, time, costs and improving quality control, as recently 
developed for CADM1-MAL-hsa-miR-124-2 and the reference gene β-actin 126. 
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Glossary 
 
Cervical intraepithelial neoplasia (CIN) also known as cervical dysplasia is a premalignant condition 
of the uterine cervix, which histologically can be subdivided into CIN1, CIN2 and CIN3. 
 
DNA methylation: Addition of a methyl-group at a cytosine in a CG dinucleotide pair. DNA 
methylation of CG-rich areas in gene promoters can result in gene silencing. 
 
Epigenetic changes: Changes in DNA methylation and chromatin, that do not involve a change in the 
DNA sequence 
 
Episome: An extrachromosomal DNA element that can replicate independently from host 
chromosomal DNA 
 
Methylation marker panel: A panel of genes,  most often involving gene promoter sequences, in which 
methylation of CG sites represent a biomarker for a specific condition, such as a (pre)cancerous lesion 
of the cervix. 
 
Microarray comparative genomic hybridization (microarrayCGH): a platform on which at a genome 
wide level DNA copy number aberrations can be assessed in a single experiment 
 
Self-sample: A self (at home)-collected cervico-vaginal specimen using a lavage or brush-based 
sampler. The self-collected cells can be used for cervical cancer screening by HPV detection and  
triage by methylation marker analysis. 
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Legends to the Figures 
 
Figure 1. HPV-mediated cervical carcinogenesis.  
 The various outcomes of exposure of cervical epithelial cells to high-risk human 
papillomavirus (hrHPV) are represented as a transient infection (no pathology), productive infection 
(productive cervical intraepithelial neoplasia (CIN); mainly representing CIN1 and subset of CIN 2) 
and transforming infection (transforming CIN; mainly representing the remaining subset of CIN2 and 
CIN 3). Morphologically, CIN2 associated with a productive HPV infection can not be distinguished 
from CIN2 associated with a transforming HPV infection. Similarly, CIN1 lesions that occasionally 
may represent transforming infections are morphologically not distinguishable from productive 
counterparts. From the onset of a transforming CIN it can take another 20-30 years before invasive 
cancer will develop. Transforming CIN represents a heterogeneous disease with varying duration of 
existence, which may either regress or progress to cancer. The risk of cancer progression is dependent 
on molecular host cell alterations.  
 A new concept suggests that most of the transforming CIN and cervical cancers arise from 
exposure of embryonic squamo-columnar junction (SCJ) cells to hrHPV 20, suggesting a high 
susceptibility of these cells for HPV transformation. The SCJ cells and corresponding lesions are 
characterized by a specific protein expression pattern (expression of Krt7, AGR2, MMP7 and GDA) 
and precursor lesions arising from these SCJ cells are unlikely to be preceded by a productive CIN. 
The latter are suggested to arise from infection of cells in the ectocervix or transformation zone. 
 
 
Figure 2. Cellular changes required for progression of transforming cervical intraepithelial 
neoplasia (CIN) to cancer.  
The human papillomavirus (HPV)-related and host cell aberrations associated with disease progression 
are indicated below the concept of HPV-induced cervical carcinogenesis. Colour intensities indicate 
their level or frequency of detection and dashed lines indicate their infrequent or unknown detection. 
The potential application of the viral and host cell aberrations as markers for screening, diagnosis and 
treatment strategies is listed on the right.  tCIN: transforming CIN; CxCa: cervical cancer 
 
Figure 3. Triage tools in cervical scrapings of human papillomavirus (HPV)-positive women.  
A schematic representation of the sensitivity (y-axis) of different triage methods for women with 
HPV-test positive cervical scrapings (blue line, host cell DNA methylation; black line, cytology) along 
the time line of transforming CIN towards invasive cervical cancer (x-axis).  
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